Drug metabolism polymorphisms as modulators of cancer susceptibility

Mutation Research - Reviews in Mutation Research

Volumn 436, Issue 3, 1999, Pages 227-261

  Taningher, Maurizio ^a   Malacarne, Davide ^a   Izzotti, Alberto ^b   Ugolini, Donatella ^a   Parodi, Silvio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer risk; Chemical carcinogenesis; Drug metabolism; Genetic polymorphism

Indexed keywords

ACYLTRANSFERASE; DEBRISOQUINE 4 HYDROXYLASE; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE TRANSFERASE;

CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033037686     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(99)00005-8     Document Type: Article

References (170)

1. Weinberg R.A. Tumor suppressor genes. Science. 254:1991;1138-1145.
2. K. Hemminki, A. Dipple, D.E.G. Shuker, et al. (Eds.), DNA Adducts: Identification and Biological Significance, Lyon, International Agency for Research on Cancer, IARC Sci. Publ. No. 125, 1994.
3. J.A. Miller, E.C. Miller, Ultimate chemical carcinogens as reactive mutagenic electrophiles, in: H.H. Hiatt, J.D. Watson, J.A. Winstein (Eds.), Origins of Human Cancer, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1977, pp. 605-628.
4. Nebert D.W., Nelson D.R., Adesnik M.et al. The P450 gene superfamily, update on the naming of new genes and nomenclature of chromosomal loci. DNA. 8:1989;1-13.
5. Gonzalez F.J. The molecular biology of the cytochrome P450s. Pharmacol. Rev. 40:1989;243-288.
6. Kellermann G., Luyte-Kellermann M., Shaw C.R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 25:1973;327-331.
7. Trell L., Korsgaard R., Janzon L.et al. Distribution and reproducibility of aryl hydrocarbon hydroxylase inducibility in a prospective study of middle-aged male smokers and nonsmokers. Cancer. 56:1985;1988-1994.
8. Nebert D.W. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. CRC Crit. Rev. Toxicol. 20:1989;153-174.
9. Nebert D.W. Role of genetics and drug metabolism in human cancer risk. Mutat. Res. 247:1991;267-281.
10. Hoffman E.C., Reyes H., Chu F.-F.et al. Cloning of a factor required for activity of Ah (Dioxin) receptor. Science. 252:1991;954-958.
11. G.W. Lucier, Receptor-mediated carcinogenesis, in: H. Vainio, P.N. Magee, D.B. McGregor, et al. (Eds.), Mechanisms of Carcinogenesis in Risk Identification, Lyon, International Agency for Research on Cancer, IARC Sci. Publ. No. 116, 1992, pp. 87-112.
12. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 35:1995;307-340.
13. Nebert D.W., Mc Kinnon R.A., Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15:1996;273-280.
14. Spurr N.K., Gough A.C., Stevenson K.et al. Msp-I polymorphism detected with a cDNA probe for the P450 1 family on chromosome 15. Nucleic Acids Res. 15:1987;5901.
15. Kawajiri K., Nakachi K., Imai K.et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphism of the cytochrome P4501A1 gene. FEBS Lett. 263:1990;131-133.
16. Cosma G., Crofts F., Currie D.et al. Racial differences in restriction fragment length polymorphisms and messenger RNA inducibility of the human CYP1A1 gene. Cancer Epidemiol. Biomarkers Prev. 2:1993;53-57.
17. Hayashi S.I., Watanabe J., Nakachi K.et al. Genetic linkage of lung cancer associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene. J. Biochem. 110:1991;407-411.
18. Crofts F., Taioli E., Trachman J.et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 15:1994;2961-2963.
19. Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun. 231:1997;227-230.
20. Rannug A., Alexandrie A.-K., Persson I.et al. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: Regulation and toxicological significance. J. Occup. Environ. Med. 37:1995;25-36.
21. Crofts F., Cosma G.N., Currie D.et al. A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis. 14:1993;1729-1731.
22. Garte S.J., Trachman J., Crofts F.et al. Distribution of composite CYP1A1 genotypes in Africans, African-Americans and Caucasians. Hum. Hered. 46:1996;121-127.
23. Cascorbi I., Brockmöller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 56:1996;4965-4969.
24. Bailey R.L., Roodi N., Verrier C.S.et al. Breast cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res. 58:1998;65-70.
25. Nakachi K., Imai K., Hayashi S.-I.et al. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res. 51:1991;5177-5180.
26. 1450) gene: lack of association between the MspI restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics. 1:1991;20-25.
27. Hirvönen A., Husgafvel-Pursiainen K., Karjalajnen A.et al. Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomarkers Prev. 1:1992;485-489.
28. Shields P.G., Caporaso N.F., Falk R.T.et al. Lung cancer, race, and CYP1A1 genetic polymorphism. Cancer Epidemiol. Biomarkers Prev. 2:1993;481-485.
29. Xu X., Kelsey K.T., Wiencke J.K.et al. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 5:1996;687-692.
30. Mannervik B., Danielson U.H. Glutathione transferase structure and catalytic activity. Crit. Rev. Biochem. Mol. Biol. 23:1988;281-337.
31. Nakachi K., Imai K., Hayashi S.et al. Polymorphism of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 53:1993;2994-2999.
32. Kihara M., Kihara M., Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis. 16:1995;2331-2336.
33. Alexandrie A.-K., Ingelman Sundberg M., Seidegård J.et al. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1: a study on best factors in relation to age at onset, gender and histological cancer types. Carcinogenesis. 15:1994;1785-1790.
34. Johnson B.S., Brooks B.A., Reyes H.et al. An MspI RFLP in human ARNT gene, encoding a subunit of the nuclear form of the Ah (dioxin) receptor. Hum. Mol. Genet. 1:1992;351.
35. Nakachi K., Hayashi S., Kawajiri K.et al. Association of cigarette smoking and CYP1A1 polymorphisms with adenocarcinoma of the lung by grades of differentiation. Carcinogenesis. 16:1995;2209-2213.
36. Anttila S., Hirvonen A., Husgafvel-Pursiainen K.et al. Combined effect of CYP1A1 inducibility and GSTM1 polymorphism on histological type of lung cancer. Carcinogenesis. 15:1994;1133-1135.
37. El-Zein R.A., Zwischenberger J.B., Abdel Rahman S.Z.et al. Polymorphism of metabolyzing genes and lung cancer histology: prevalence of CYP2E1 in adenocarcinoma. Cancer Lett. 112:1997;71-78.
38. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5′ flanking region change transcriptional regulation of the human cytochrome P450 IIE1 gene. J. Biochem. 100:1991;559-564.
39. Uematsu F., Kikuchi H., Motomiya M.et al. Association between restriction fragment length polymorphism of the human cytochrome P450 IIE1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 87:1991;254-256.
40. Uematsu F., Ikawa S., Kikuchi H.et al. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450 IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics. 4:1994;58-63.
41. Goto I., Yoneda S., Yamamoto M.et al. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 56:1996;3725-3730.
42. Giovannucci E., Rimm E.B., Stampfer M.J.et al. A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. men. J. Natl. Cancer Inst. 86:1994;183-191.
43. Gerhardsson de Verdier M., Hagman U., Peters R.K.et al. Meat, cooking methods and colorectal cancer: a case-referent study in Stockholm. Int. J. Cancer. 49:1991;520-525.
44. Sivaraman L., Leatham M.P., Yee J.et al. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res. 54:1994;3692-3695.
45. Taioli E., Trachman J., Chen X.et al. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res. 55:1995;3757-3758.
46. Ambrosone C.B., Freudenheim J.L., Graham S.et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res. 55:1995;3483-3485.
47. Ishibe N., Hankinson S.E., Colditz G.A.et al. Cigarette smoking, cytochrome P450 1A1 polymorphisms and breast cancer risk in the Nurses' Health Study. Cancer Res. 58:1998;667-671.
48. Fontana X., Peyrotte I., Valente E.et al. Glutathion S-transférase mu 1 (GSTM1): gène de susceptibilité du cancer du sein. Bull. Cancer. 84:1997;35-40.
49. Edeki T. Clinical importance of genetic polymorphism of drug oxidation. Mt. Sinai J. Med. 63:1996;291-300.
50. Crespi C.L., Penman B.W., Gelboin H.V.et al. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s, including the polymorphic cytochrome P4502D6. Carcinogenesis. 12:1991;1197-1201.
51. Smith G., Stanley L.A., Sim E.et al. Metabolic polymorphisms and cancer susceptibilities. Cancer Surv. 25:1995;27-65.
52. Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:1997;269-296.
53. Sachse C., Brockmöller J., Bauer S.et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60:1997;284-295.
54. Stuven T., Griese E.U., Kroemer H.K.et al. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics. 6:1996;417-421.
55. Chen S., Chou W.H., Blouin R.A.et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. 60:1996;522-534.
56. Ayesh R., Idle J.R., Ritchie J.C.et al. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature. 312:1984;169-170.
57. Kaisary A., Smith P., Jaczq E.et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res. 47:1987;5488-5493.
58. Wolf C.R., Smith C.A.D., Gough A.L.et al. Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis. 13:1992;1035-1038.
59. Preston-Martin S., Pike M.C., Ross R.K.et al. Increased cell division as a cause of human cancer. Cancer Res. 50:1990;7415-7421.
60. B.E. Butterworth, J.A. Popp, R.B. Conolly, et al., Chemically induced cell proliferation in carcinogenesis, in: H. Vainio, P.N. Magee, D.B. McGregor, et al. (Eds.), Mechanisms of Carcinogenesis in Risk Identification, Lyon, International Agency for Research on Cancer, IARC Sci. Publ. No. 116, 1992, pp. 279-305.
61. Bouchardy C., Benhamou S., Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 56:1996;251-253.
62. Kihara M., Kihara M., Noda K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis. 15:1994;415-418.
63. Kato S., Bowman K.D., Harrington A.M.et al. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl. Cancer Inst. 87:1995;902-907.
64. London S.J., Daly A.K., Leathart J.B.S.et al. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis. 18:1997;1203-1214.
65. Stücker I., Cosme J., Laurent Ph.et al. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis. 16:1995;2759-2764.
66. Christensen P.M., Gotzsche P.C., Brosen K. The sparteine/debrisoquine (CYP2D6) polymorphism and the risk of lung cancer: a meta-analysis. Eur. J. Clin. Pharmacol. 51:1997;389-393.
67. Gold L.S., Slone T.H., Bernstein L. Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. Environ. Health Perspect. 79:1989;259-272.
68. Hoffmann D., Brunnemann K.D., Prokopczyk B.et al. Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Toxicol. Environ. Health. 44:1994;1-52.
69. International Agency for Research on Cancer, Chemistry and analysis of tobacco smoke, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, 38 (1986) 83-126.
70. Elexpuru-Camiruaga J., Buxton N., Kandula V.et al. Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res. 55:1995;4237-4239.
71. Pickett C.B., Lu A.Y.H. Glutathione S-transferases: gene structure, regulation, and biological function. Annu. Rev. Biochem. 58:1989;743-764.
72. Mannervik B. Glutathione peroxidase. Methods Enzymol. 113:1985;490-495.
73. Mannervik B., Awasthi Y.C., Board P.G.et al. Nomenclature for human glutathione transferases. Biochem. J. 282:1992;305-306.
74. Ketterer B., Harris J.M., Talaska G.et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ. Health Perspect. 98:1992;87-94.
75. Berhane K., Widersten M., Engström Å.et al. Detoxication of base propenals and other α,β-unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. Proc. Natl. Acad. Sci. U.S.A. 91:1994;1480-1484.
76. Seidegård J., Vorachek W.K., Pero R.W.et al. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. U.S.A. 85:1988;7293-7297.
77. Pemble S., Schroeder K.R., Spencer S.R.et al. Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem. J. 300:1994;271-276.
78. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family. Regulation of GST and the contribution of the isoenzymes in cancer chemoprevention and drug resistance. Crit. Rev. Biochem. Mol. Biol. 30:1995;445-600.
79. Lin H.J., Han C.-Y., Bernstein D.A.et al. Ethnic distribution of the glutathione transferase Mu 1-1 (GSTM1) null genotype in 1473 individuals and application to bladder cancer susceptibility. Carcinogenesis. 15:1994;1077-1081.
80. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev. 6:1997;733-743.
81. Schröder K.R., Hallier E., Peter H.et al. Dissociation of a new glutathione S-transferase activity in human erythrocytes. Biochem. Pharmacol. 43:1992;1671-1674.
82. Chen C.L., Liu Q., Relling M.V. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics. 6:1996;187-191.
83. Abdel Rahman S.Z., El-Zein R.A., Anwar W.A.et al. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett. 107:1996;229-233.
84. Inskip A., Elexpuru-Camiruaga J., Buxton N.et al. Identification of polymorphism at the glutathione S-transferase GSTM3 locus: evidence for linkage with GSTM1*A. Biochem. J. 312:1995;713-716.
85. Anttila S., Luostarinen L., Hirvonen A.et al. Pulmonary expression of glutathione S-transferase M3 in lung cancer patients: association with GSTM1 polymorphism, smoking, and asbestos exposure. Cancer Res. 55:1995;3305-3309.
86. Yengi L., Inskip A., Gilford J.et al. Polymorphism at the glutathione S-transferase locus GSTM3: interactions with cytochrome P450 and glutathione S-transferase genotypes as risk factors for multiple cutaneous basal cell carcinoma. Cancer Res. 56:1996;1974-1977.
87. Board P.G., Weber G.C., Coggan M. Isolation of a cDNA clone and localization of the human glutathione S-transferase 3 genes to chromosome bands 11q3 and 12q13-14. Ann. Hum. Genet. 53:1989;205-213.
88. Ali-Osman F., Akande O., Antoun G.et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. J. Biol. Chem. 272:1997;10004-10012.
89. Zimniak P., Nanduri B., Pikula S.et al. Natutally occurring human glutathione S-transferase GSTP1-1 isoforms with isoleucine and valine in position 104 differ in enzymatic properties. Eur. J. Biochem. 224:1994;893-899.
90. Watson M.A., Stewart R.K., Smith G.B.J.et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis. 19:1998;275-280.
91. Harries L.W., Stubbins M.J., Forman D.et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis. 18:1997;641-644.
92. Seidegård J., Pero R.W., Miller D.G.et al. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 7:1986;751-753.
93. van Poppel G., de Vogel N., van Balderen P.J.et al. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme μ Carcinogenesis. 13:1992;303-305.
94. Scarpato R., Hirvonen A., Migliore L.et al. Influence of GSTM1 and GSTT1 polymorphisms on the frequency of chromosome aberrations in smokers and pesticide-exposed greenhouse workers. Mutat. Res. 389:1997;227-235.
95. Liu Y.H., Taylor J., Linko P.et al. Glutathione S-transferase μ in human lymphocyte and liver: role in modulating formation of carcinogen-derived DNA adducts. Carcinogenesis. 12:1991;2269-2275.
96. Shields P.G., Bowman E.D., Harrington A.M.et al. Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 53:1993;3486-3492.
97. Grinberg-Funes R.A., Singh V.N., Perera F.P.et al. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione S-transferase genotype. Carcinogenesis. 15:1994;2449-2454.
98. Ryberg D., Hewer A., Phillips D.H.et al. Different susceptibility to smoking-induced DNA damage among male and female cancer patients. Cancer Res. 54:1994;5801-5803.
99. Ryberg D., Skaug V., Hewer A.et al. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 18:1997;1265-1289.
100. McWilliams J.E., Sanderson B.J., Harris E.L.et al. Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol. Biomarkers Prev. 4:1995;589-594.
101. To-Figueras J., Gené M., Gómez-Catalán J.et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans. Carcinogenesis. 18:1997;1529-1533.
102. Brockmöller J., Kerb R., Drakoulis N.et al. Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res. 54:1994;4103-4111.
103. Brockmöller J., Cascorbi I., Kerb R.et al. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56:1996;3915-3925.
104. Jahnke V., Matthias C., Fryer A.et al. Glutathione S-transferase and cytochrome-P-450 polymorphism as risk factors for squamous cell carcinoma of the larynx. Am. J. Surg. 172:1996;671-673.
105. Heagerty A.H.M., Fitzgerald D., Smith A.et al. Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous tumors. Lancet. 343:1994;266-268.
106. Zhong S., Wyllie A.M., Barnes D.et al. Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis. 14:1993;1821-1824.
107. Lafuente A., Pujol F., Carretero P.et al. Human glutathione S-transferase μ (GSTμ) deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett. 68:1993;49-54.
108. Trizna Z., Clayman G.L., Spitz M.R.et al. Glutathione S-transferase genotypes as risk factors for head and neck cancer. Am. J. Surg. 170:1995;499-501.
109. Kihara M., Kihara M., Kubota A.et al. GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. Cancer Lett. 112:1997;257-262.
110. Oude Ophuis M.B., van Lieshout E.M., Roelofs H.M.et al. Glutathione S-transferase M1 and T1 and cytochrome P450 1A1 polymorphisms in relation to the risk for benign and malignant head and neck lesions. Cancer. 82:1998;936-943.
111. Jourenkova N., Reinikainen M., Bouchardy C.et al. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol. Biomarkers Prev. 7:1998;19-23.
112. Anwar W.A., Abdel-Rahman S.Z., El-Zein R.A.et al. Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis. 17:1996;1923-1929.
113. Katoh T., Inatomi H., Nagaoka A.et al. Cytochrome P4501A1 gene polymorphism and homozygous deletion of the glutathione S-transferase M1 gene in urothelial cancer patients. Carcinogenesis. 16:1995;655-657.
114. Katoh T., Nagata N., Kuroda Y.et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) genetic polymorphism and susceptibility to gastric and colorectal adenocarcinoma. Carcinogenesis. 17:1996;1855-1859.
115. Chenevix-Trench G., Young J., Coggan M.et al. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility to colon cancer and age of onset. Carcinogenesis. 16:1995;1655-1657.
116. Deakin M., Elder J., Hendrickse C. Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis. 17:1996;881-884.
117. Lin H.J., Probst-Hensch N.M., Ingles S.A.et al. Glutathione transferase (GSTM1) null genotype, smoking, and prevalence of colorectal adenomas. Cancer Res. 55:1995;1224-1226.
118. Szarka C.E., Pfeiffer G.R., Hum S.T.et al. Glutathione S-transferase μ expression in subjects with risk for colorectal cancer. Cancer Res. 55:1995;2789-2793.
119. Ashby J., Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat. Res. 257:1991;229-306.
120. Matthias C., Bockmuhl U., Jahnke V.et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacogenetics. 8:1998;1-6.
121. Heagerty A., Smith A., English J.et al. Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione transferase GSTM1 genotypes, skin type and male gender. Br. J. Cancer. 73:1996;44-48.
122. Lear J.T., Heagerty A.H.M., Smith A.et al. Multiple cutaneous basal cell carcinomas: glutathione S-transferase (GSTM1, GSTT1) and cytochrome P450 (CYP2D6, CYP1A1) polymorphisms influence tumour number and accrual. Carcinogenesis. 17:1996;1891-1896.
123. Gonzalez, Role of cytochrome P-450 1A1 in skin cancer, in: H. Mukhatar (Ed.), Skin Cancer: Mechanisms and Human Relevance, CRC Press, Boca Raton, FL, 1995, pp. 89-97.
124. Lear J.T., Smith A.G., Heagerty A.H.M.et al. Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma. Carcinogenesis. 18:1997;1499-1503.
125. Hein D.W., Doll M.A., Rustan T.D.et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and NAT2 acetyltransferases. Carcinogenesis. 14:1993;1633-1638.
126. Kadlubar F.F., Butler M.A., Kaderlik K.R.et al. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect. 98:1992;69-74.
127. Hickman D., Risch A., Buckle V.et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem. J. 297:1994;441-445.
128. Grant D.M., Vohra P., Avis Y.et al. Detection of a new polymorphism of human arylamine N-acetyltransferase (NAT1) using p-aminosalicylic acid as an in vivo probe. J. Basic Clin. Physiol. Pharmacol. 3:1992;244. Suppl.
129. Weber W.W., Vatsis K.P. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltransferase (NAT1) of peripheral blood. Pharmacogenetics. 3:1993;209-212.
130. Vatsis K.P., Weber W.W. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch. Biochem. Biophys. 301:1993;71-76.
131. Vatsis K.P., Weber W.W., Bell D.A.et al. Nomenclature of N-acetyltransferases. Pharmacogenetics. 5:1995;1-17.
132. Bell D.A., Stephens E.A., Castranio T.C.et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res. 55:1995;3537-3542.
133. Bell D.A., Badawi A.F., Lang N.P.et al. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55:1995;5226-5229.
134. Badawi A.F., Hirvonen A., Bell D.A.et al. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 55:1995;5230-5237.
135. Payton M.A., Sim E. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem. Pharmacol. 55:1998;361-366.
136. Evans D.A.P. N-acetyltransferase. Pharmacol. Ther. 42:1989;157-234.
137. Blum M., Demierre A., Grant D.M.et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5237-5241.
138. Deguchi T., Mashimo M., Suzuki T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver. J. Biol. Chem. 265:1990;12757-12760.
139. Hein D.W., Ferguson R.J., Doll M.A.et al. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet. 3:1994;729-734.
140. Cascorbi I., Drakoulis N., Brockmöller J.et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am. J. Hum. Genet. 57:1995;581-592.
141. Sugimura T., Sato S. Mutagens-carcinogens in food. Cancer Res. 43:1983;2415s-2421s. Suppl.
142. Grant D.M., Josephy P.D., Lord H.L.et al. Salmonella typhimurium strains expressing human arylamine N-acetyltransferases: metabolism and mutagenic activation of aromatic amines. Cancer Res. 52:1992;3961-3964.
143. Lower G.M. Jr., Nilsson T., Nelson C.E.et al. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect. 29:1979;71-79.
144. Cartwright R.A., Glashan R.W., Rogers H.J.et al. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetics epidemiological approach to bladder cancer. Lancet. 2:1982;842-846.
145. Evans D.A.P., Eze L.C., Whibley E.J. The association of the slow acetylator phenotype with bladder cancer. J. Med. Genet. 20:1983;330-333.
146. Vineis P., Bartsch H., Caporaso N.et al. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 369:1994;154-156.
147. Risch A., Wallace D.M.A., Bathers S.et al. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 4:1995;231-236.
148. Hickman D., Risch A., Camilleri J.P.et al. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics. 2:1992;217-226.
149. Okkels H., Sigsgaard T., Wolf H.et al. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphism in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev. 6:1997;225-231.
150. Söderkvist P., Axelson O. On the use of molecular biology data in occupational and environmental epidemiology. J. Occup. Environ. Med. 37:1995;84-90.
151. Lang N.P., Chu D.Z.J., Hunter C.F.et al. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg. 121:1986;1259-1261.
152. Ilett K.F., Beverley M.D., Detchon P.et al. Acetylation phenotype in colorectal carcinoma. Cancer Res. 47:1987;1466-1469.
153. Shibuta K., Nakashima T., Abe M.et al. Molecular genotyping for NAT polymorphism in Japanese patients with colorectal cancer. Cancer. 74:1994;3108-3112.
154. Spurr N.K., Gough A.C., Chinegwundoh F.J.et al. Polymorphisms in drug-metabolizing enzymes as modifiers of cancer risk. Clin. Chem. 41:1995;1864-1869.
155. Probst-Hensch N.M., Haile R.W., Ingles S.A.et al. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res. 55:1995;2017-2020.
156. Probst-Hensch N.M., Haile R.W., Li D.S.et al. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis. 17:1996;2125-2129.
157. Welfare M.R., Cooper J., Bassendine M.F.et al. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis. 18:1997;1351-1354.
158. Gil J.P., Lechner M.C. Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Carcinogenesis. 19:1998;37-41.
159. Ambrosone C.B., Freudenheim J.L., Graham S.et al. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. J. Am. Med. Assoc. 276:1996;1494-1501.
160. Lin H.J. Smokers and breast cancer. 'Chemical individuality' and cancer predisposition. J. Am. Med. Assoc. 276:1996;1511-1512.
161. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
162. Cahill D.P., Lengauer C., Yu J.et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 392:1998;300-303.
163. Modrich P. Mismatch repair, genetic stability, and cancer. Science. 266:1994;1959-1960.
164. Sancar D.A. DNA repair in humans. Annu. Rev. Genet. 29:1995;69-105.
165. S. Garte, C. Zocchetti, E. Taioli, Gene-environment interactions in the application of biomarkers of cancer susceptibility in epidemiology, in: P. Toniolo, P. Boffetta, D.E.G. Shuker, et al. (Eds.), Application of Biomarkers in Cancer Epidemiology, Lyon, International Agency for Research on Cancer, IARC Sci. Publ. No. 142, 1997, pp. 251-264.
166. Cascorbi I., Brockmöller J., Mrozikiewicz P.M.et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 56:1996;3961-3966.
167. Jakoby W.B., Habig W.H. Glutathione transferases. Enzym. Basis of Detoxification. 2:1980;63-94.
168. DeFlora S., Cesarone C.F., Balansky R.M.et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell. Biochem. 22:1995;33-41. Suppl.
169. Pennisi E. From genes to genome biology. Science. 272:1996;1736-1738.
170. Hieter P., Boguski M. Functional genomics: it's all how you read it. Science. 278:1997;601-602.